TEVA vs. UTHR: Teva Pharmaceutical vs. United Therapeutics Stock Comparison

Company Profile

Teva Pharmaceutical (TEVA) and United Therapeutics (UTHR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but TEVA is classified in Pharmaceuticals while UTHR is classified in Biotechnology.

United Therapeutics (UTHR) trades as ordinary local shares, while Teva Pharmaceutical (TEVA) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Teva Pharmaceutical (TEVA) at 6.65% and United Therapeutics (UTHR) at 19.13% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

United Therapeutics (UTHR) at 38.61% converts revenue to bottom-line profit above its industry’s benchmark range, while Teva Pharmaceutical (TEVA) at 2.94% keeps roughly the typical share for its industry.

Both Teva Pharmaceutical (TEVA) at 27.40% and United Therapeutics (UTHR) at 28.99% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Teva Pharmaceutical (TEVA) at 4.31% and United Therapeutics (UTHR) at 10.61% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: United Therapeutics (UTHR) reports EPS growth of 13.07%, ranked against its industry; Teva Pharmaceutical (TEVA) has no EPS growth figure this period.

Growth Metrics

Financial Strength

United Therapeutics (UTHR) at 4.61 keeps current ratio within its industry’s typical mid-range, while Teva Pharmaceutical (TEVA) at 0.95 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TEVA.

Only one side’s leverage can be read here: Teva Pharmaceutical (TEVA) carries debt-to-equity ratio of 2.13 against its industry range, while United Therapeutics (UTHR) reports no figure this period.

Financial Strength Metrics

Dividends

Neither Teva Pharmaceutical (TEVA) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Teva Pharmaceutical (TEVA) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

United Therapeutics (UTHR) at 21.22 is near its industry’s usual P/E ratio, while Teva Pharmaceutical (TEVA) at 99.09 sits above its peer range — an unusually expensive price for TEVA’s trailing earnings.

Teva Pharmaceutical (TEVA) at 2.89 sits in the cheaper P/S ratio quartile while United Therapeutics (UTHR) at 7.51 prices around its industry’s middle — TEVA costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Teva Pharmaceutical (TEVA) at 6.23 and United Therapeutics (UTHR) at 3.80 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics